39 results about "Cathepsin B" patented technology

The invention discloses an electrochemical urine biopsy system for cathepsin B analysis and a detection method of the electrochemical urine biopsy system. The electrochemical urine biopsy system comprises gold nanoparticles AuNPs, a peptide-peptide nucleic acid PNA series probe and an electrochemical sensor. The peptide-peptide nucleic acid tandem probe is combined with gold nanoparticles through a mercaptan modified sequence to form a spherical nanostructure with the diameter of 15 nm, a polypeptide substrate sequence serves as a specific reaction substrate of cathepsin B, and PNA provides stability and a signal shielding function. The electrochemical sensor is based on a cutting enzyme-assisted DNAwalker mechanism, signal amplification is started through methylene blue MB release, and high-sensitivity detection of the released PNA probe is achieved. The system provided by the invention has the characteristics of high specificity, high sensitivity and rapid response, can realize quantitative analysis of cathepsin B through noninvasive urine biopsy, and provides a new technical means for early diagnosis and treatment monitoring of tumors.

The invention relates to a radioactive metal labeled antibody obtained by labeling an antibody with a radioactive metal. A functional chelate linker is coupled to the antibody, and the functional chelate linker is provided with: a chelate part capable of coordinating with a radioactive metal ion; and a functional unit having a function of improving intracellular retention. It is preferable that the functional unit has a structure obtained by polymerizing ethyleneimine or ethylene glycol, or a structure capable of binding to cathepsin B. The functional unit preferably has a structure obtained by polymerizing ethyleneimine at a degree of polymerization of 1-7 (inclusive).

The invention discloses a glucan-based MMAE conjugate as well as a preparation method and application thereof, and relates to the technical field of medicines. The conjugate takes glucan with good biocompatibility as a carrier, and is covalently connected with a cytotoxic drug MMAE through a VC peptide linker capable of being cut by cathepsin B. The conjugate has good serum stability, can specifically release drugs at a tumor site, and realizes efficient tumor uptake by virtue of the stealth effect of glucan and potential GLUT1 targeting. In-vitro and animal experiments show that the conjugate has a remarkable treatment effect on pancreatic cancer and is low in systemic toxicity.

The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

This invention discloses an enzyme- and pH-responsive nucleic acid loading and delivery material and its preparation method. The material can be used for efficient loading and delivery of nucleic acid molecules. The preparation method uses amphiphilic zwitterionic monomers to improve the reverse emulsion polymerization system, enhancing polymerization at the two-phase interface and avoiding the extrusion effect of polymerization in the aqueous core on nucleic acid molecules, thereby improving the loading efficiency of nucleic acid molecules. Further preparation of cross-linking agents MP-CL and CB-CL, which can cleave in response to matrix metalloproteinase II or cathepsin B, endows the nanogel with the ability to respond to charge reversal in the tumor matrix and to release nucleic acid molecules from tumor cells. The acid-sensitive blocks on the amphiphilic monomers give the nanogel lysosomal escape capability. The delivery material can efficiently deliver nucleic acid molecules into cells and exhibits excellent stability and biosafety.

The invention discloses an albumin coupling medicine as well as a preparation method and application thereof. The cathepsin B response type camptothecin albumin coupling drug is innovatively designed and synthesized by taking albumin as a carrier, the albumin coupling drug has good cathepsin B response drug release capability, efficient tumor targeted delivery of the drug is realized, camptothecin is responded and released in tumor cell lysosome, and the drug delivery efficiency is improved. The specific anti-tumor effect is achieved. The invention provides a regulation and control method in the aspects of preparation, drug loading capacity and in-vitro release of the albumin coupled drug, size effects in the aspects of cellular uptake, cytotoxicity, tumor targeting and retention are illustrated, and guidance is provided for designing an efficient and safe tumor drug delivery system.

Compositions and methods are provided of a therapeutic nanoparticle composed of collagenase IV linked via a linker (e.g. cathepsin B cleavable linker) to ferumoxytol (iron oxide). The collagenase IV is key in the composition intended for the breakdown of the tumor wall as the collagenase. Such compositions and methods are aimed at solving at the same time two of the main challenges of current approaches in the treatment of glioblastoma multiforme (GBM) which are low specificity and poor uptake.

The invention discloses a cathepsin B activated chemiluminescent nanoparticle. The cathepsin B activated chemiluminescent nanoparticle is prepared from cat B-C-550, hypericin and DSPE-mPEG2000 (Distearoyl Phosphate Polyethylene-mPEG (Polyethylene Glycol) 2000 in a self-assembly manner; the structure of the cat B-C-550 is as shown in a formula I in the specification. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of reagents or drugs for screening or diagnosing tumors. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of a cancer imaging reagent and / or a medicine for treating tumors. According to the invention, chemiluminescence imaging and in-situ cancer PDT treatment without external exciting light are realized. The cat B enzyme response type chemiluminescent nanoparticles are high in stability and can be effectively targeted and enriched at tumor focus parts.

The invention belongs to the field of biological medicine, and particularly relates to a nano-drug based on chondroitin sulfate as well as a preparation method and application of the nano-drug. Chondroitin sulfate (CS) and dasatinib (DAS) are connected through a GFLG connexon responded by cathepsin B (CTSB) to prepare the prodrug CS-GFLG-DAS (CGD), the prodrug CS-GFLG-DAS (CGD) is used for reversing the phenotype of cancer-related fibroblasts and reducing the biosynthesis of extracellular matrixes, fibrotic tumors are efficiently treated, and a new perspective is provided for optimizing the application of immunotherapy in fibrotic tumors.

The invention relates to the field of biological medicine, in particular to an endoplasmic reticulum targeting peptide, an agonist, a preparation method and application. Wherein the agonist comprises an endoplasmic reticulum targeting peptide, and further comprises a mitochondrial membrane disturbing sequence and a sequence with cathepsin B response, the mitochondrial membrane disturbing sequence is KLAKLAK 2, and the sequence with cathepsin B response is GFLG; the endoplasmic reticulum targeting peptide comprises a KKKAA peptide sequence, and chlorin e6 and R8 peptide are connected to the KKKAA peptide sequence; the mitochondrial membrane disturbing sequence is connected to the R8 peptide through a sequence with cathepsin B response. According to the scheme, the characteristics of biochemical information interaction and tumor growth regulation of the mitochondria and the endoplasmic reticulum are utilized, excessive stress of the endoplasmic reticulum and a mitochondria calcium uptake channel are activated at the same time in a safe and controllable mode, free Ca < 2 + > in the endoplasmic reticulum rapidly flows into the mitochondria, the steady states of the endoplasmic reticulum and the mitochondria of tumor cells are damaged, and the tumor growth is controlled. And the two synergistically induce cells to start an apoptosis procedure, so that the aim of treating diseases is fulfilled.

The invention relates to a cathepsin B sensitive fatty acid-adriamycin prodrug as well as albumin nanoparticles, a preparation method and application thereof, and belongs to the technical field of medicines. The cathepsin B sensitive fatty acid-adriamycin prodrug is a prodrug as shown in a formula (I), a geometric isomer thereof, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by entrapping the cathepsin B sensitive fatty acid-adriamycin prodrug by using human / bovine serum albumin as a carrier. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug adriamycin after being taken by tumor cells and hydrolyzed by cathepsin B; therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.

The present invention provides the application of the secretory protein CTSB (cathepsin B) in predicting the risk of vascular lesions in patients with diabetic foot ulcers (DFUs), belonging to the field of biomedicine technology. Through single-cell sequencing studies, the present invention found that the secretory protein CTSB is significantly enriched in vascular endothelial cells in the blood vessels of DFU patients, with high PPI connectivity and low expression; CTSB overexpression / knockout experiments found that CTSB is associated with the proliferation and tubulogenesis of vascular endothelial cells in human blood vessels; ELISA experiments also found that the level of secretory protein CTSB in serum can be used as a marker for predicting the risk of vascular lesions in DFU patients, and that the expression level of CTSB is negatively correlated with the Wanger grade of diabetic foot; the method can predict the risk of peripheral vascular lesions in DFU patients, has the advantages of simple operation and high sensitivity, can reduce false detection and missed detection, and has stable and reliable test results, making it suitable for large-scale detection.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The present disclosure relates to a cancer-targeting peptide that can be cleaved by cathepsin B in cancer cells and is characterized by forming prodrug nanoparticles together with an anticancer agent, wherein the preparation of carrier-free prodrug nanoparticles may provide a new approach to cancer treatment and may significantly improve cancer targeting and the therapeutic efficacy of an anticancer agent.

The application discloses application of cathepsin E in preparation of a drug for treating or preventing lung cancer, relates to the technical field of biological medicine, and first proves that CTSE is highly expressed in lung adenocarcinoma tissues and has the biological function of inhibiting lung cancer cell proliferation through clinical sample analysis, cell function experiment and animal experiment. Mechanism research shows that CTSE plays the anticancer role by down-regulating the expression of cathepsin B (CTSB) and promoting the degradation of STING protein through a lysosome pathway and inhibiting the cGAS-STING natural immune pathway. The application clarifies the application value of CTSE as a new target for treating lung adenocarcinoma, provides a theoretical basis and experimental basis for developing a novel lung cancer treatment drug, and has an important clinical application prospect.

The invention relates to application of HDAC (histone deacetylase) inhibitor and Cathepsin B inhibitor combined medicine in lung cancer treatment, and belongs to the technical field of biological medicine. Research finds that histone deacetylase inhibitors (HDAC inhibitors, HDACIs) can promote invasion and migration of tumor cells by inducing epithelial-mesenchymal transition while inhibiting tumor growth, and side effects are generated. Therefore, in order to inhibit the side effect and enable the HDAC inhibitor to effectively exert the curative effect clinically, the invention provides a novel medicine combination mode, the HDAC inhibitor and the Cathepsin B inhibitor are combined for use, so that the antitumor activity of the HDAC inhibitor is retained, the tumor invasion and migration capability induced by the HDAC inhibitor is effectively inhibited, and the curative effect of the HDAC inhibitor is effectively exerted clinically. A new strategy is provided for precise treatment of solid tumors, and the method is verified in treatment of lung cancer.

The invention discloses an efficient fluorescein probe as well as a preparation method and application thereof, and relates to the field of fluorescein probes. The high-efficiency fluorescein probe prepared by the invention has an extremely low detection limit on cathepsin B, has excellent fluorescence performance and good biocompatibility, is suitable for detection of tumor-related cathepsin B, and has important application significance in the aspect of early diagnosis of tumors.

The invention provides a preparation method and application of a multi-target enzymatic self-assembly fluorescence activated nanoprobe, and belongs to the field of pharmacy. According to the method, an Fmoc solid-phase peptide synthesis strategy is adopted, an N end is connected with a fluorescence quencher Dabcyl, a C end is marked with fluorescein, a near C end is a self-assembly sequence Y (pY) YG capable of generating self-assembly behavior through dephosphorylation of alkaline phosphatase, and a middle section is a cleavage sequence KGGFLGK capable of being cleaved into a fluorescent'switch 'by cathepsin B; the near N end is a functional polypeptide F-pY-LyP-1 of a targeting sequence CGNKRTRGC or LyP-1 which can be highly combined with a p32 receptor on the surface of a foam cell. The fluorescence activated nanoprobe accurately reaches a plaque part under the synergistic effect of multiple target points and is self-assembled into spherical nanoparticles, so that the aggregation and retention effects of the probe in the plaque are improved, the non-specific signal interference is reduced, and the early atherosclerotic plaque is more accurately identified.

This invention provides an activatable semiconductor polymer, its preparation method, and its applications. The activatable semiconductor polymer of this invention can efficiently accumulate at tumor sites. Due to the presence of electron-withdrawing groups on its side chains, the polymer's fluorescence is quenched. Upon response to tumor markers—biothiols, reactive oxygen species, and cathepsin B—the polymer's fluorescence recovers, enabling precise imaging and sonodynamic therapy at the tumor site. Simultaneously, the activatable semiconductor polymer of this invention can label immune cells (such as dendritic cells and macrophages) and track their metastasis from the tumor to the draining lymph nodes.

The invention belongs to the technical field of antibody preparation, and particularly relates to an antibody for resisting human cathepsin B, an antibody pair, a kit and application thereof. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The invention provides two antibodies capable of specifically, accurately, sensitively and reliably detecting the content of human cathepsin B, an antibody pair composed of the antibodies and a kit containing the antibodies or the antibody pair, and the antibodies or the antibody pair have good practical application value in the field of immunodiagnosis and treatment of CTSB abnormal diseases.

The antibody is a radioactive metal-labeled antibody including an antibody labeled with a radioactive metal. The radioactive metal-labeled antibody further includes a functional chelate linker conjugated to the antibody, and, the functional chelate linker includes: a chelating moiety capable of coordinating to a radioactive metal ion; and a functional unit having a function of enhancing intracellular retention. The functional unit preferably has a structure in which ethyleneimine or ethylene glycol is polymerized or a structure capable of binding to cathepsin B. The functional unit preferably has a structure in which ethyleneimine is polymerized with a polymerization degree of 1 to 7.

The application discloses a cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The cell-penetrating peptide modified enzyme-sensitive PDC type PROTAC is obtained by modifying a cell-penetrating peptide and an enzyme-sensitive linker (GFLG) to a PROTAC of an anti-tumor drug target protein ligand, has the ability to release the PDC type PROTAC under catalysis of cathepsin B, has a smaller influence on cell viability of U251 cells, U87 cells and HEK293 cells, has proliferation inhibition activity on the U251 cells and the U87 cells, can degrade target proteins in the U251 cells and the U87 cells, can induce apoptosis of the U251 cells and the U87 cells, has an influence on U251 cell cycles, can be used for preparing an anti-tumor drug (target protein degradation and membrane penetration), has a good application prospect in preparation of a drug for targeting human brain glioma cells, and can be used as another important field for PROTAC drug development.

This invention relates to a cathepsin B-sensitive fatty acid-doxacin prodrug, its albumin nanoparticles, preparation method, and application, belonging to the field of pharmaceutical technology. The cathepsin B-sensitive fatty acid-doxacin prodrug is defined as the prodrug shown in general structural formula (I), its geometric isomers, and its pharmaceutically acceptable salts, hydrates, and solvates; where n = 0-14. Further, the cathepsin B-sensitive fatty acid-doxacin prodrug is encapsulated using human / bovine serum albumin as a carrier to prepare bound albumin nanoparticles. These albumin nanoparticles have a small and uniform particle size, exhibiting good placement and colloidal stability. They remain stable in systemic circulation and normal tissues. However, after being taken up by tumor cells, they are hydrolyzed by cathepsin B to release the parent drug doxacin, thereby achieving specific killing of tumor cells without producing serious toxic side effects, showing promising clinical development prospects.

This invention discloses an enzyme-sensitive PDC-type PROTAC modified with a human leukemia cell-targeting transmembrane peptide, its preparation method, and its applications, belonging to the field of tumor targeted therapy technology. This PDC-type PROTAC is composed of a hypoxia-inducible factor 1α (HIF-1α) protein fragment linked to imatinib via dodecanoic acid, and further modified with the human leukemia cell-targeting transmembrane peptide Cyclo-C9C-R and the cathepsin B-sensitive sequence GFLG. The modified PDC-type PROTAC can release the original drug under the catalysis of cathepsin B, with minimal impact on THP1 cell viability, but effectively inhibits the proliferation of K562 and KU812 cells, degrades target proteins, induces apoptosis, and affects the cell cycle. This gives the PDC-type PROTAC significant advantages in the preparation of anti-tumor drugs, particularly showing promising application prospects in the development of drugs targeting human chronic myeloid leukemia cells and human peripheral blood basophilic leukemia cells, opening up a new field for PROTAC drug development.

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

The invention discloses an application of brown planthopper Cathepsin B protein in prevention and treatment of brown planthopper, and relates to the technical field of biological prevention and treatment of brown planthopper. By inhibiting the expression of the coding gene of the Cathepsin B protein in the brown planthopper, the growth and development of the brown planthopper can be obviously inhibited; the method has wide application prospect and great application value in the fields of pesticide use reduction, ecological balance maintenance, sustainable development and the like.

The invention discloses an enzyme response near-infrared two-region fluorescence / computed tomography dual-mode imaging probe based on a gold nano-cluster and a preparation method and application of the enzyme response near-infrared two-region fluorescence / computed tomography dual-mode imaging probe. The probe comprises: a gold nanocluster capable of simultaneously providing near-infrared two-region fluorescence and computed tomography imaging signals; the polypeptide molecule is modified on the surface of the material. The polypeptide comprises a cathepsin B response sequence, biotin with a targeting function and a click reaction unit 2-cyanobenzothiazole. The probe disclosed by the invention is subjected to enzyme digestion and trigger click reaction under the action of highly expressed CTSB in liver cancer cells, so that the gold nanoclusters are subjected to cross-linked aggregation at tumor parts, the retention time of the probe is prolonged, NIR-II fluorescence and CT imaging effects are remarkably enhanced, and high-sensitivity detection on liver cancer is realized.

This invention discloses a Trichinella spiralis cathepsin B, its encoding gene, and its applications, belonging to the field of genetic engineering technology. This invention utilizes a food-grade L. lactis expression system to construct a lactic acid bacteria expression system for the TsCB gene. By orally administering the recombinant L. lactis strain pNZ8149-TsCB / L. lactis NZ3900 to mice, a type 2 immune response can be induced, increasing the recruitment of M2 macrophages, reducing neutrophil infiltration, and inhibiting the expression of pro-inflammatory factors and inflammatory mediators, thereby improving colitis in DSS mice. This lays the foundation for the subsequent development of food-grade oral parasite-derived molecular drugs for the treatment of colitis.

The invention belongs to the field of biological medicine, and provides an active compound for treating prostatic cancer and a preparation method thereof. A-B-C-D-P five-module linear connection design is adopted, wherein the A module is a prostate specific membrane antigen targeting binding unit, the B module is a prostate specific antigen enzyme digestion recognition sequence HSSKLQ, the C module is a cathepsin B-responsive Val-Cit-p-aminobenzyl self-destruction unit, the D module is a reduction-responsive disulfide bond connecting arm, and the P is an anti-tumor pharmacodynamic fragment. A coupling reaction is accurately controlled through a continuous flow microchannel technology, controllable self-assembly of the 20-60-nanometer nano aggregate is achieved, the average hydration diameter dispersion coefficient is not larger than 0.20, and the nano aggregate stably exists in plasma and selectively releases drugs in a tumor microenvironment. Multiple contradictions among prodrug system process manufacturability, intracellular response release and stable dispersion of the preparation are solved, and wide clinical application value is achieved.

The invention relates to a cathepsin B sensitive fatty acid-avitecan prodrug, albumin nanoparticles thereof, a preparation method and application, and belongs to the technical field of medicines. The cathepsin B-sensitive fatty acid-avitecan prodrug is a prodrug as shown in a formula (I), a geometric isomer of the prodrug, and pharmaceutically acceptable salts, hydrates and solvates of the prodrug, wherein n is equal to 0-14. The invention also relates to a combined albumin nanoparticle prepared by using human / bovine serum albumin as a carrier to encapsulate a cathepsin B sensitive fatty acid-etiotecan prodrug. The albumin nanoparticles are small in particle size and uniform in form, have good placement stability and colloidal stability, can stably exist in systemic circulation and normal tissues, and release a parent drug, namely avixetecan after being taken by tumor cells and hydrolyzed by cathepsin B, so that the albumin nanoparticles can be used for treating tumor tumors. Therefore, specific killing of tumor cells is realized without generation of serious toxic and side effects, and good clinical development prospects are achieved.